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ABSTRACT
Background and Objectives: Little is known about the outcomes of outpatient clinic-based 
elective external cardioversion (OPC-ECV) for persistent atrial fibrillation (PeAF). We investigated 
the acute, short-term, and long-term elective external cardioversion (ECV) outcomes.
Methods: We included 1,718 patients who underwent OPC-ECV (74% male, 61.1±11.0 years 
old, 90.9% long-standing PeAF, 9.1% after atrial fibrillation [AF] ablation) after excluding 
patients with atrial tachycardia or inappropriate antiarrhythmic drug medication, and 
in-patient ECV. Biphasic shocks were delivered sequentially until successful cardioversion 
was achieved (70-100-150-200-250 J). If ECV failed at 150 J, we administered intravenous 
amiodarone 150 mg and delivered 200 J.
Results: ECV failed in 11.4%, and the complication rate was 0.47%. Within 3 months, AF 
recurred in 55.5% (44.7% as sustaining AF, 10.8% as paroxysmal AF), and the AF duration 
was independently associated (odds ratio [OR], 1.01 [1.00–1.02]; p=0.006), but amiodarone 
was independently protective (OR, 0.46 [0.27–0.76]; p=0.002, Log rank p<0.001) against an 
early recurrence. Regarding the long-term recurrence, pre-ECV heart failure was protective 
against an AF recurrence (hazard ratio, 0.63 [0.41–0.96], p=0.033) over 32 (9–66) months of 
follow-up. ECV energy (p<0.001) and early recurrence rate within 3 months (p=0.007, Log 
rank p=0.006) were significantly lower in post-ablation patients than in those with long-
standing persistent AF.
Conclusions: The success rate of OPC-ECV was 88.6%, and the complication rate was low. 
However, AF recurred in 55.5% within 3 months. Amiodarone was protective against short-term 
AF recurrences, and long-term AF recurrences were less in patients with baseline heart failure.
Keywords: Atrial fibrillation; Cardioversion; Recurrence
INTRODUCTION
Atrial fibrillation (AF) is a common rhythm disorder with a prevalence of 1–2% in the total 
population, with an increasing prevalence with age.1) Although rhythm control of AF may 
reduce heart failure mortality,2) cardiovascular mortality and hospitalization,3) and incidence 
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of stroke,4) and improve cognitive5) and renal functions,6) most studies have been evaluated 
after aggressive rhythm control of AF by catheter ablation. As a traditional intervention for 
rhythm control, elective external cardioversion (ECV) is commonly used to treat persistent 
AF (PeAF). Although ECV has a high acute success rate for restoring sinus rhythm, its rate of 
sinus rhythm maintenance is low when using antiarrhythmic drugs (AADs).7) The outcome of 
ECV can vary greatly with the duration of AF,8) the type of AAD used,7) the ECV shock energy 
form and energy level,9) the location of the paddles,9) and the rhythm follow-up protocol 
after ECV.10) In previous studies on ECV, acute and short-term success rates were commonly 
evaluated within 1 month by combining the 2.8) Only a few previous studies have evaluated 
the effects of ECV in highly selective patient groups, such as long-standing PeAF or post-
AF catheter ablation (AFCA) PeAF.11) Moreover, only a few studies have been conducted on 
elective ECV performed in an outpatient clinic rather than ECV performed in an emergency 
room or intensive care unit.12)13)
The purpose of this study was to evaluate the efficacy and safety of outpatient clinic-based 
ECV in a protocol-based single center prospective registry. The aims of this study were 
to evaluate the acute success rate after outpatient clinic-based ECV, short-term rhythm 
outcomes within 3 months, and long-term outcomes after 3 months and to identify factors 
associated with these rhythm outcomes. We also compared ECV outcomes between patients 
with long-standing PeAF and those in whom AFCA.
METHODS
Study population
The study protocol adhered to the Declaration of Helsinki. All patients provided written 
informed consent. From March 2009 to November 2018, a total of 1,893 long-standing 
PeAF patients who underwent ECV at Severance Hospital were enrolled. After excluding 175 
patients with atrial tachycardia (AT), inappropriate AAD medication, or in-patient ECV, 1,718 
patients were included (74% males, 61.1± 11.0 years). Among all included individuals, 1,561 
patients (90.9%) had long-standing PeAF, and 157 (9.1%) patients had PeAF after AFCA. 
According to the American College of Cardiology (ACC)/American Heart Association (AHA) 
Task Force on Practice Guidelines and the Heart Rhythm Society (HRS) Expert Consensus 
Statement guidelines,14) long-standing PeAF was defined as AF lasting for longer than 1 year. 
Anti-coagulation therapy was maintained at least 3 weeks before ECV.
Echocardiogram and medical therapy
All patients underwent trans-thoracic echocardiography (Sonos 5500, Philips Medical 
System, Andover, MA, USA; or Vivid 7, GE Vingmed Ultrasound, Horten, Norway) prior to 
ECV. Left atrial (LA) chamber size (LA dimension and LA volume index), ejection fraction, 
the ratio of early diastolic mitral inflow velocity (E) to early diastolic mitral annular velocity 
(Em), and other data were acquired according to the American Society of Echocardiography 
guidelines.15) Transesophageal echocardiography was performed in the majority of the 
patients with a high risk of a stroke or high CHA2DS2-VASc score (≥2) based on the physician's 
discretion (358 patients, Supplementary Table 1).
We prescribed AADs in 96.5% of the patients at least 1 month before the ECV. In the 
remaining 3.5% of patients, the ECV was conducted without AADs because of significant 
sinus node dysfunction or adverse effects of the drugs. Physicians chose AADs based on 
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current guidelines after evaluating the comorbidities of patients.14) The general dosages of 
each AAD were amiodarone 200–400 mg, dronedarone 400–800 mg, sotalol 80–160 mg, 
flecainide 150–200 mg, and propafenone 300–450 mg per day. AADs were maintained after 
successful ECV, but stopped in recurred patients. We reduced doses of amiodarone to 100 mg 
per day when the patient maintained sinus rhythm on the post-ECV Holter in the third month 
to minimize long-term adverse effects.
Anticoagulation was maintained according to guidelines at least 4 weeks after outpatient-
based ECV.14) After that period, we maintained anticoagulation based on CHA2DS2-VASc score 
regardless of rhythm status.
Electrical cardioversion
We performed ECV for rhythm control in AAD-resistant AF patients based on current 
guidelines.14) All ECV procedures were scheduled and performed at an outpatient clinic 
under sedation (intravenous pentothal [1.5–2.0 mg/kg]). ECV was applied uniformly using 
2 oval adhesive pre-gelled pads (each pad, 78 cm2 area) placed in an anterior-posterior 
position between the right sternal body at the third intercostal space and the area of the left 
scapular angle within the 3rd to 5th intercostal space by a physician.9) ECV was performed 
as a QRS-synchronized biphasic direct current shock (biphasic, Medtronic LIFEPACKVR 20; 
Physio-Control, Inc., Redmond, WA, USA) that began with 70 J and was serially increased 
to 100 J and then 150 J until sinus rhythm was achieved. If sinus rhythm was not achieved 
after ECV with 150 J, or if immediate recurrence of AF developed, 150 mg amiodarone 
intravenous infusion over 20 minutes, and ECV was serially increased to 200 J and then 250 
J.16) We defined successful cardioversion as restoration and maintenance of sinus rhythm by 
ECV until the patient had left the clinic. Anticoagulation was strictly maintained within the 
therapeutic range before and after ECV.14)
Follow-up and terminology
After successful cardioversion, we checked outpatient ECG at 2 weeks after ECV and 24-hour 
Holter 3 months later and every 6 months thereafter, unless AF recurred. Whenever the patient 
reported symptoms of palpitations suggestive of arrhythmia recurrence, Holter ECG or event 
monitor recordings were obtained. We defined recurrence of AF as any episode of AF or AT 
of at least 30 seconds in duration.14) If any ECG documented an AF/AT episode within the 
3-month blanking period during follow-up, the patient was diagnosed with early recurrence. 
Any AF/AT recurrence thereafter was diagnosed as long-term recurrence.14)
We cited the 2014 ACC/AHA/HRS Expert Consensus Statement guidelines to define 
paroxysmal AF14) and also cited the 2016 European Society of Cardiology guidelines for the 
diagnosis and treatment of acute and chronic heart failure to define heart failure.17)
Data analysis
We compared clinical characteristics, echocardiographic findings, cardioversion parameters, 
and medications in terms of successful electrical cardioversion. Continuous variables were 
described as means±standard deviations or median (25–75 percentile) and were compared 
by analysis of variance. A χ2 test was used for the categorical variables. The independent 
t-test was used to compare the continuous variables between 2 groups in Tables 1 and 2. The 
analysis of variance test was performed for the continuous variables among the groups in 
Table 3, and paired t-test was used to investigate changes in echocardiographic parameters 
before and after cardioversion. We analyzed factors associated with clinical recurrence after 
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cardioversion of AF by Cox proportional hazard model analysis and factors associated with 
early recurrence by logistic regression analysis. If any variable had a statistically significant 
difference (p value <0.05) in the univariate analysis, we entered it into the multivariate 
analysis. The age and gender were the 2 default variables included in the multivariate analysis, 
regardless of the p value. A Kaplan-Meier survival analysis was conducted to determine the 
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Table 1. Baseline characteristics of acute outcome of outpatient clinic-based ECV
Overall (n=1,718) Success (n=1,523) Fail (n=195) p value
Age (years) 61.1±11.0 61.2±11.1 60.1±10.2 0.177
Male 1,272 (74.0) 1,133 (74.4) 139 (71.3) 0.351
Body weight (kg) 72.3±18.3 72.4±18.8 72.1±13.5 0.844
BMI (kg/m2) 25.5±10.6 25.5±11.1 25.8±6.3 0.681
AF duration (months) 43.4±58.2 43.6±58.6 38.7±43.3 0.804
Post-AFCA 157 (9.1) 143 (9.4) 14 (7.2) 0.313
CHA2DS2-VASc 1.9±1.6 1.9±1.6 1.8±1.5 0.219
Heart failure 223 (13.0) 197 (12.9) 26 (13.3) 0.876
Hypertension 901 (52.4) 801 (52.6) 100 (51.3) 0.730
Age >75 years 178 (10.4) 163 (10.7) 15 (7.7) 0.194
Age 65–74 years 701 (40.8) 634 (41.6) 67 (34.4) 0.052
Diabetes 303 (17.6) 259 (17.0) 44 (22.6) 0.055
Stroke/TIA 197 (11.5) 182 (12.0) 15 (7.7) 0.079
Vascular disease 83 (4.8) 74 (4.9) 9 (4.6) 0.881
eGFR (mL/min/1.73 m2) 76.1±15.6 75.9±15.9 77.6±13.0 0.117
Hemoglobin (g/dL) 14.8±2.6 14.8±2.7 14.7±2.0 0.756
Echocardiogram data
LA dimension (mm) 45.6±6.4 45.6±6.5 46.2±5.5 0.180
LAVI (mL/m2) 48.3±19.0 48.1±18.3 50.3±23.7 0.227
Ejection fraction (%) 60.2±10.1 60.1±10.1 60.5±9.6 0.633
E/Em 11.5±5.3 11.5±5.4 11.4±5.1 0.702
Antiarrhythmic drugs 1,658 (96.5) 1,472 (96.7) 186 (95.4) 0.364
Amiodarone 767 (46.3) 679 (46.1) 88 (47.3) 0.760
Dronedarone 131 (7.9) 117 (7.9) 14 (7.5) 0.841
Sotalol 74 (4.5) 64 (4.3) 10 (5.4) 0.522
Flecainide 547 (33.0) 492 (33.4) 55 (29.6) 0.292
Propafenone 98 (5.9) 84 (5.7) 14 (7.5) 0.321
Pilsicainide 41 (2.5) 36 (2.4) 5 (2.7) 0.841
ACEi/ARB 301 (17.5) 275 (18.1) 26 (13.3) 0.102
b-blocker 484 (28.2) 432 (28.4) 52 (26.7) 0.620
Statin 310 (18.0) 276 (18.1) 34 (17.4) 0.815
Values are presented as number (%) or mean±standard deviation.
ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ARB = angiotensin receptor blocker; BMI = 
body mass index; E = early diastolic mitral inflow velocity; ECV = elective external cardioversion; eGFR = estimated glomerular filtration rate by Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation; Em = early diastolic mitral annular velocity; LA = left atrial; LAVI = left atrial volume index; TIA = 
transient ischemic attack.
Table 2. Comparison of the outpatient clinic-based ECV outcomes between the L-PeAF and post-AFCA patients
Overall (n=1,718) L-PeAF (n=1,561) Post-AFCA (n=157) p value
ECV success 1,523 (88.6) 1,380 (88.4) 143 (91.1) 0.313
Successful ECV energy (J) 144.0±69.5 146.2±69.1 122.2±70.0 <0.001
Major complication 8 (0.47) 8 (0.51) 0 (0.0) 0.369
Stroke 2 (0.12) 2 (0.13) 0 (0.0)
TIA 1 (0.06) 1 (0.07) 0 (0.0)
SND requiring admission 5 (0.29) 5 (0.31) 0 (0.0)
AF recurrence within 3 months 845 (55.5) 781 (56.6) 64 (44.8) 0.007
AF recurrence after 3 months 323 (47.6) 281 (46.9) 42 (53.2) 0.296
Follow-up months (25–75 percentile) 32 (9–66) 31 (9–65) 41 (17–79) 0.001
Values are presented as number (%) or mean±standard deviation.
AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ECV = electrical cardioversion; L-PeAF = long-standing persistent atrial fibrillation; TIA = 
transient ischemic attack; SND = sinus node dysfunction.
probability of freedom from arrhythmia recurrence after cardioversion. The p values <0.05 
were considered indicative of statistical significance. All analyses were performed using SPSS 
20.0 (SPSS, Chicago, IL, USA).
RESULTS
Acute outcomes of outpatient clinic-based ECV
Among the 1,718 patients included in this study, outpatient clinic-based ECV successfully 
restored sinus rhythm in 1,523 (88.6%) and failed in 195 (11.4%, Figure 1). The required 
energy for successful ECV was 144.0±69.5 J. There were no significant differences in baseline 
characteristics between the successful ECV and failed ECV groups (Table 1). No parameters 
were independently associated with failed ECV in multivariate logistic regression analysis 
(Supplementary Table 2). The complication rate after outpatient clinic-based ECV was 
0.47%: 3 patients experienced minor stroke or transient ischemic attack (TIA; 0.18%), and 5 
patients had significant sinus node dysfunction requiring admission (0.29%, Table 2).
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Table 3. Characteristics based on outpatient clinic-based ECV outcome within 3 months
Overall (n=1,523) Remain in NSR (n=678) Recur as PAF (n=164) Recur as sustaining AF (n=681) p value
Age (years) 61.2±11.1 61.9±11.4 62.0±11.6 60.4±10.7 0.037
Male 1,133 (74.4) 503 (74.2) 114 (69.5) 516 (75.8) 0.254
BMI (kg/m2) 25.5±11.1 25.3±7.6 25.7±6.7 25.6±14.3 0.870
AF duration (months) 43.6±58.6 15.0±18.4 30.5±41.1 50.7±65.1 0.003
Post-AFCA 143 (9.4) 79 (55.2) 16 (11.2)) 48 (33.6) 0.014
CHA2DS2-VASc 1.9±1.6 2.0±1.6 2.0±1.5 1.9±1.6 0.552
Heart failure 197 (12.9) 92 (13.6) 26 (15.9) 79 (11.6) 0.278
Hypertension 801 (52.6) 366 (54.0) 84 (51.2) 351 (51.5) 0.622
Age >75 years 163 (10.7) 82 (12.1) 19 (11.6) 62 (9.1) 0.189
Age 65–74 634 (41.6) 300 (44.2) 78 (47.6) 256 (37.6) 0.012
Diabetes 259 (17.0) 112 (16.5) 34 (20.7) 113 (16.6) 0.405
Stroke/TIA 182 (12.0) 75 (11.1) 14 (8.5) 93 (13.7) 0.122
Vascular disease 74 (4.9) 38 (5.6) 5 (3.0) 31 (4.6) 0.347
eGFR (mL/min/1.73 m2) 75.9±15.9 75.6±16.0 74.8±16.7 76.6±15.7 0.321
Hemoglobin (g/dL) 14.8±2.7 14.8±3.5 14.5±2.0 14.8±1.7 0.086
Echocardiogram data
LA dimension (mm) 45.6±6.5 45.3±6.5 46.7±7.4 45.5±6.2 0.067
Ejection fraction (%) 60.1±10.1 60.3±10.2 57.8±11.5 60.5±9.7 0.023
E/Em 11.5±5.4 11.8±5.7 12.6±6.5 11.0±4.6 0.003
Successful ECV energy (J) 123.9±43.9 118.0±42.6 118.9±45.0 131.1±43.8 <0.001
Antiarrhythmic drugs 1,472 (96.7) 651 (96.0) 162 (98.8) 659 (96.8) 0.205
Amiodarone 679 (46.1) 346 (53.1) 75 (46.3) 258 (39.2) <0.001
Dronedarone 117 (7.9) 45 (6.9) 8 (4.9) 64 (9.7) 0.056
Sotalol 64 (4.3) 24 (3.7) 6 (3.7) 34 (5.2) 0.389
Flecainide 492 (33.4) 193 (29.6) 65 (40.1) 234 (35.5) 0.013
Propafenone 84 (5.7) 37 (5.7) 5 (3.1) 42 (6.4) 0.271
Pilsicainide 36 (2.4) 6 (0.9) 3 (1.9) 27 (4.1) 0.001
ACEi/ARB 275 (18.1) 153 (22.6) 27 (16.5) 95 (14.0) <0.001
b-blocker 432 (28.4) 208 (30.7) 46 (28.0) 178 (26.1) 0.178
Statin 276 (18.1) 145 (21.4) 22 (13.4) 109 (16.0) 0.009
Values are presented as number (%) or mean±standard deviation.
ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ARB = angiotensin receptor blocker; BMI = 
body mass index; E = early diastolic mitral inflow velocity; ECV = electrical cardioversion; eGFR, estimated glomerular filtration rate by Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation; Em = early diastolic mitral annular velocity; LA = left atrial; NSR = normal sinus rhythm; PAF = persistent atrial 
fibrillation; TIA = transient ischemic attack.
Short-term outcomes after successful ECV
Among 1,523 patients in whom outpatient clinic-based ECV was successful, 681 patients 
(44.7%) recurred with sustaining AF, 164 patients (10.8%) recurred with paroxysmal AF, and 
678 (44.5%) remained in sinus rhythm within 3 months under AAD (Table 3). Among the 
patients who remained in sinus rhythm within 3 months of ECV, AF duration was shorter 
(p=0.003) and the proportions of post-AFCA state (p=0.014), amiodarone users (p<0.001), 
and statin users (p=0.009) were significantly higher than those with early AF recurrence 
(Table 3). A multivariate logistic regression analysis showed that the AF duration (odds 
ratio [OR], 1.01 [1.00–1.02]; p=0.006) and amiodarone (OR, 0.46 [0.27–0.76]; p=0.002) 
were independently associated with a short-term recurrence within 3 months (Table 4). 
Maintaining amiodarone was protective against early AF recurrence within 3 months of ECV 
(Log rank p<0.001, Figure 2A).
Long-term outcomes after ECV
Table 5 summarizes the baseline characteristics according to long-term recurrence after 3 
months of outpatient clinic-based ECV. Among 678 patients who maintained sinus rhythm for 
longer than 3 months, 323 patients (47.6%) experienced a recurrence of AF during a median 
of 32 (9–66) months of follow-up. The patients who remained in sinus rhythm had more heart 
failure (p<0.001) with lower ejection fraction (p=0.002) before ECV and comprised more 
β-blocker users (p=0.003) than those with long-term recurrence. Among 92 patients who 
experienced pre-ECV heart failure, the ejection fraction (49.4±12.5% to 56.2±11.8%, p<0.001) 
and left ventricular (LV) end-systolic dimension (39.9±7.4 mm to 37.9±5.8 mm, p=0.015) 
were significantly improved in follow-up echocardiogram at 23.2±25.1 months after ECV 
(Supplementary Table 3). In Cox regression analysis, baseline heart failure was independently 
associated with long-term AF recurrence after outpatient clinic-based ECV (hazard ratio, 0.63 
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Excluding 175 patients due to AT,
inappropriate AAD and in-patient ECV
Dividing 2 groups
After ECV
Short-term: ECG 2 weeks,
24 hours Holter 3 months later
Long-term: total 1,523 successful ECV
patients: 24 hours Holter every 6 months
(still in sinus rhythm)
355 no AF recurrence 323 AF recurrence















143 success 14 failure
1,893 patients underwent ECV
1,561 long-standing PeAF 157 post-AFCA
Figure 1. Flowchart of including, excluding and dividing PeAF patients into 2 groups: L-PeAF and post-AFCA. 
AAD = antiarrhythmic drug; AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; AT = atrial tachycardia; ECG = electrocardiogram; ECV = elective 
external cardioversion; L-PeAF = long-standing persistent atrial fibrillation; PAF = paroxysmal atrial fibrillation; PeAF = persistent atrial fibrillation.
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Table 4. Logistic regression analysis for early AF recurrence within 3 months of ECV
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Age (years) 0.99 (0.98–1.00) 0.051 0.99 (0.96–1.01) 0.278
Male 1.02 (0.81–1.29) 0.870 1.18 (0.66–2.12) 0.577
BMI (kg/m2) 1.00 (0.99–1.01) 0.609 - -
AF duration (months) 1.01 (1.00–1.01) 0.006 1.01 (1.00–1.02) 0.006
Post-AFCA 0.62 (0.44–0.88) 0.007 0.42 (0.14–1.21) 0.107
CHA2DS2-VASc 0.98 (0.92–1.05) 0.587 - -
Heart failure 0.90 (0.67–1.22) 0.509 - -
Hypertension 0.90 (0.74–1.11) 0.331 - -
Diabetes 1.06 (0.81–1.39) 0.651 - -
Stroke 1.16 (0.85–1.60) 0.339 - -
Vascular disease 0.75 (0.47–1.20) 0.227 - -
LA dimension (mm) 1.01 (0.99–1.03) 0.207 - -
Ejection fraction (%) 1.00 (0.99–1.01) 0.472 - -
E/Em 0.98 (0.96–1.00) 0.069 - -
Successful ECV energy (J) 1.24 (1.13–1.37) <0.001 1.26 (1.00–1.60) 0.052
Antiarrhythmic drugs 1.42 (0.81–2.48) 0.220 - -
Amiodarone 0.60 (0.49–0.74) <0.001 0.46 (0.27–0.76) 0.002
ACEi/ARB 0.58 (0.45–0.75) <0.001 0.88 (0.48–1.63) 0.690
b-blocker 0.82 (0.65–1.02) 0.073 - -
Statin 0.67 (0.52–0.88) 0.003 0.92 (0.52–1.64) 0.777
ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ARB, 
angiotensin receptor blocker; BMI = body mass index; CI = confidence interval; E = early diastolic mitral inflow velocity; 
ECV = elective external cardioversion; Em = early diastolic mitral annular velocity; LA = left atrial; OR = odds ratio.
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Figure 2. Kaplan-Meier curves for AF recurrence-free survival rate in short-term (above) and long-term (beneath) follow-up after successful ECV between groups 
L-PeAF, heart failure, amiodarone (red line) and post-AFCA, non heart failure, non-amiodarone (blue line). 
AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ECV = elective external cardioversion; L-PeAF = long-standing persistent atrial fibrillation; PeAF 
= persistent atrial fibrillation.
[0.41–0.96]; p=0.033, Table 6). In Kaplan-Meier analysis, underlying hear failure was protective 
against long-term recurrence of AF after ECV (Log rank p=0.024, Figure 2B). However, 
amiodarone did not affect the long-term rhythm outcomes of ECV (Figure 2A).
Although the early recurrence of AF was significantly higher in patients with a successful ECV 
with ≤150 J (Log rank p=0.003), the late recurrence rate did not differ between the ECV ≤150 J 
group and ECV >150 J group (Supplementary Figure 1). The early and late recurrence rates of 
AF did not significantly differ between the patients who underwent pre-ECV transesophageal 
echocardiography and those who did not (Supplementary Figure 1). The early and late 
recurrence rates of AF did not significantly differ between the patients with associated 
structural heart disease and those without (Supplementary Figure 1).
Long-standing PeAF versus post-AFCA recurrent AF
Among 1,718 patients who underwent outpatient clinic-based ECV, we compared 1,561 patients 
with long-standing PeAF and 157 patients with recurred AF after AFCA (Table 2). Although 
ECV success rates (p=0.313) or major complication rates (p=0.369) did not significantly differ, 
the energy level of successful ECV was significantly higher in patients with long-standing 
PeAF (146.2±69.1 J) than in those with a post-AFCA state (122.2±70.0 J, p<0.001). Early AF 
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Table 5. Patient characteristics for long-term AF recurrence after 3 months of ECV
Overall (n=678) No AF recurrence (n=355) AF recurrence (n=323) p value
Age (years) 61.9±11.4 62.3±11.4 61.4±11.4 0.327
Male 503 (74.2) 273 (76.9) 230 (71.2) 0.091
BMI (kg/m2) 25.4±7.6 25.1±3.0 25.7±10.6 0.294
AF duration (months) 28.8±35.6 15.0±18.4 29.1±35.9 0.582
L-PeAF 599 (88.3) 318 (53.1) 281 (46.9) 0.296
Post-AFCA 79 (11.7) 37 (46.8) 42 (53.2) 0.296
CHA2DS2-VASc 2.0±1.6 2.1±1.7 1.9±1.5 0.068
Heart failure 92 (13.6) 67 (18.9) 25 (7.7) <0.001
Hypertension 366 (54.0) 197 (55.5) 169 (52.3) 0.408
Age >75 years 82 (12.1) 47 (13.2) 35 (10.8) 0.338
Age 65–74 years 300 (44.2) 173 (48.7) 127 (39.3) 0.014
Diabetes 112 (16.5) 58 (16.3) 54 (16.7) 0.894
Stroke 75 (11.1) 40 (11.3) 35 (10.8) 0.858
Vascular disease 38 (5.6) 23 (6.5) 15 (4.6) 0.300
eGFR (mL/min/1.73 m2) 75.6±16.0 75.2±16.1 76.1±15.9 0.465
Hemoglobin (g/dL) 14.8±3.5 14.7±2.0 14.9±4.6 0.438
Echocardiogram data
LA dimension (mm) 45.3±6.5 45.3±6.5 45.4±6.5 0.934
Ejection fraction (%) 60.3±10.2 59.1±11.0 61.7±9.1 0.002
E/Em 11.8±5.7 11.9±5.9 11.8±5.5 0.760
Successful ECV energy (J) 118.0±42.6 116.6±41.9 119.6±43.3 0.361
Antiarrhythmic drugs 651 (96.0) 336 (94.6) 315 (97.5) 0.056
Amiodarone 346 (51.0) 178 (50.1) 168 (52.0) 0.927
Dronedarone 45 (6.6) 29 (8.2) 16 (5.0) 0.074
Sotalol 24 (3.5) 9 (2.5) 15 (4.6) 0.159
Flecainide 193 (28.5) 93 (26.2) 100 (31.0) 0.256
Propafenone 37 (5.5) 24 (6.8) 13 (4.0) 0.097
Pilsicainide 6 (0.9) 3 (0.8) 3 (0.9) 0.937
ACEi/ARB 153 (22.6) 87 (24.5) 66 (20.4) 0.205
b-blocker 208 (30.7) 127 (35.8) 81 (25.1) 0.003
Statin 145 (21.4) 80 (22.5) 65 (20.1) 0.444
Values are presented as number (%) or mean±standard deviation.
ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ARB = angiotensin receptor blocker; BMI = body 
mass index; L-PeAF = long-standing persistent atrial fibrillation; E = early diastolic mitral inflow velocity; ECV = elective external cardioversion; eGFR = estimated 
glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; Em = early diastolic mitral annular velocity; LA = left atrial.
recurrence rate within 3 months of ECV was significantly higher in patients with long-standing 
PeAF (56.6%) than in those with post-AFCA (44.8%, p=0.007; Log rank p<0.001, Figure 2C). 
However, there was no significant difference in long-term AF recurrence after 3 months of ECV 
(p=0.296, Log rank p=0.501, Figure 2C).
DISCUSSION
In this single center prospective registry study, we investigated factors associated with 
acute success, early AF recurrence, and long-term recurrence after outpatient clinic-based 
ECV. This study has several characteristics. First, we included a relatively homogeneous 
group of patients who underwent ECV on an elective schedule in an outpatient clinic and 
excluded ECV cases in the emergency room or intensive care unit. Second, we performed 
protocol-based ECV with serial increases in ECV energy. Third, rhythm follow-up after ECV 
was monitored by Holter monitoring in accordance with the fixed period, and recurrence 
of asymptomatic paroxysmal AF could be found. After protocol-based ECV under AAD, the 
acute success rate was 88.6%, and the complication rate was 0.47%. Among the patients with 
a successful ECV, AF recurred in 55.5% within 3 months, and another 52.4% of the patients 
who maintained sinus rhythm for 3 months, experienced a recurrence of AF after a median 
follow-up period of 32 (9–66) months. Amiodarone was protective against short-term AF 
recurrence, and baseline heart failure was protective against long-term AF recurrence with 
significant improvement of LV function after ECV. We also found that successful ECV energy 
and early recurrence rate within 3 months were significantly lower in post-ablation patients 
than in those with long-standing PeAF.
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Table 6. Cox regression analysis for long-term AF recurrence after 3 months of ECV
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Age (years) 0.99 (0.98–1.00) 0.030 0.99 (0.98–1.00) 0.084
Male 0.80 (0.63–1.02) 0.075 - -
BMI (kg/m2) 1.00 (0.99–1.01) 0.882 - -
AF duration (months) 1.00 (1.00–1.00) 0.885 - -
L-PeAF 0.97 (0.70–1.34) 0.829 - -
Post-AFCA 1.04 (0.75–1.43) 0.829 - -
CHA2DS2-VASc 0.93 (0.86–1.00) 0.039 1.03 (0.93–1.14) 0.585
Heart failure 0.63 (0.42–0.95) 0.028 0.60 (0.40–0.92) 0.019
Hypertension 0.79 (0.63–0.98) 0.030 0.79 (0.61–1.03) 0.078
Diabetes 0.92 (0.68–1.23) 0.553 - -
Stroke 1.03 (0.72–1.46) 0.877 - -
Vascular disease 0.74 (0.44–1.24) 0.251 - -
LA dimension (mm) 1.00 (0.98–1.02) 0.931 - -
Ejection fraction (%) 1.01 (1.00–1.02) 0.231 - -
E/Em 0.98 (0.96–1.01) 0.141 - -
Successful ECV energy (J) 1.05 (0.95–1.16) 0.359 - -
Antiarrhythmic drugs 1.66 (0.82–3.34) 0.160 - -
Amiodarone 1.08 (0.86–1.35) 0.508 - -
ACEi/ARB 1.05 (0.80–1.37) 0.752 - -
b-blocker 0.87 (0.68–1.12) 0.278 - -
Statin 1.00 (0.76–1.31) 0.996 - -
AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ACEi = angiotensinconverting enzyme inhibitor; 
ARB = angiotensin receptor blocker; BMI = body mass index; CI = confidence interval; E = early diastolic mitral 
inflow velocity; ECV = elective external cardioversion; Em = early diastolic mitral annular velocity; L-PeAF = long-
standing persistent atrial fibrillation; LA = left atrial; OR = odds ratio.
ECV has been used as an effective rhythm control method for PeAF.9)11) However, it is known 
that the recurrence rate of AF is relatively high after the procedure.18) AF duration,11) LA size,18) 
comorbidity,18) method of cardioversion,9) and drug selection7) have been shown to affect the 
outcomes of ECV. An acute outcome reflects an assessment of the electrical intervention of 
ECV itself; however, the early recurrence of AF after restoration of sinus rhythm determines 
AAD responsiveness. In this study, the mean successful ECV energy was 144 J, utilizing 
biphasic shock and defibrillation patches. Therefore, it would be reasonable to start the 
ECV at 150 J in similar patients with AF. Although the ECV acute success rate was similar to 
previous studies,10)12) we could not find any independent risk factor for ECV failure.
A major concern of outpatient clinic-based ECV might be complication risk. However, ECV 
has been deemed as a low risk procedure even in the presence of significant heart disease 
in previous studies12)13) and in this study. In the present study, there was a complication rate 
of 0.47%: sinus node dysfunction requiring hospitalization was 0.29% and minor stroke/
TIA comprised 0.18%. There were no complications associated with anesthesia. All patients 
underwent anticoagulation for more than 3 weeks before ECV. One of the patients who 
experienced peri-procedural stroke/TIA had a CHA2DS2-VASc score of 6, and 2 of them had 
score of 3 and a prior history of ischemic stroke. All 3 patients recovered neurologically.
Amiodarone is a mixed ion channel blocker with additional anti-adrenergic effects and 
significantly reduce the rate of recurrence of paroxysmal and PeAF.19)20) Because of a high rate 
of long-term adverse effects, amiodarone is generally reserved for patients with congestive 
heart failure or as a second-line AAD.14) However, rhythm control effects after restoring 
sinus rhythm were significantly superior with amiodarone than with sotalol or propafenone 
in patients with PeAF.19)20) In the SAFE-T trial,20) 1-year sinus rhythm maintenance rate was 
significantly higher in the amiodarone group than in the sotalol group (52% vs. 32%), 
although spontaneous sinus conversion rate and ECV success rate did not differ. In this 
study, amiodarone was superior to other AADs in regards to short-term rhythm outcomes 
within 3 months after ECV; however, there was no difference in ECV success rate or long-
term rhythm outcomes.
The energy requirement for successful ECV was significantly lower in post-AFCA patients 
than in the long-standing PeAF patients. AFCA for AF has beneficial effects via multiple 
mechanisms,21) including isolation or abolition of trigger foci, in both PV and extra-PV 
sites,22) as well as modulation of autonomic innervation.23) Hwang et al.21) reported that 
wide circumferential PV isolation and linear ablations also reduce cardioversion threshold 
by reducing atrial critical mass. Although the short-term rhythm outcomes of ECV were 
better in patients with post-AFCA recurrence than in those with long-standing PeAF, acute 
success and long-term recurrence rates did not differ between the 2 groups, consistent with 
a previous report.
The presence of symptomatic systolic and diastolic LV dysfunction has been shown to have 
a negative impact upon ECV success and 30-day outcomes of cardioversion.7) LV dysfunction 
can lead to increases in atrial pressure and LV hypertrophy, facilitating AF maintenance or AF 
recurrence after ECV. However, better long-term success of ECV has been shown in patients 
with associated heart failure in this study with significant improvement of LV function in 
follow-up echocardiogram. For this reason, the majority of heart failure patients included in 
this study were estimated to have tachycardiomyopathy24) or AF induced cardiomyopathy.25) 
AF itself is a major risk factor of new-onset heart failure,26) and irregular ventricular activation 
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alters myocardial gene expression, modulating calcium handling, cell function, and 
sympathetic activation.27) Therefore, long-term maintenance of sinus rhythm after successful 
ECV improved heart failure and reduced LA size, vice versa. It was reported that the 
absence of coronary artery disease, significant structural heart disease, or late gadolinium 
enhancement in cardiac magnetic resonance imaging predict improvement in heart failure 
after rhythm control of AF in patients with associated LV dysfunction.28)29)
This study was an observational cohort study from a single center that included highly 
selected patients referred for AF rhythm control. This study might have a selection bias for 
the baseline characteristics of the patients, such that our outcomes of outpatient clinic-based 
ECV cannot be generalized to all AF patients. The follow-up duration had a non-standard 
distribution in this study (32 [9–66] months). It was due to the very high chance of an early 
AF recurrence after the ECV, but a minority of the patients maintained sinus rhythm over a 
long follow-up period. We determined AF duration based on the first ECG documentation 
point because asymptomatic AF is common. The AAD dose was dependent on the physician's 
judgment rather than the strict protocol. Because we included the post-AFCA patient group, 
the study population was heterogeneous and could not represent the pure anti-arrhythmic 
drug effects. The ECG parameters are utilized in the prediction of the rhythm outcome after 
the ECV, but anti-arrhythmic drugs also remarkably affect the ECG parameters depending on 
their kind and dosage. Although we used the anterior-posterior placement for the electrode 
pads, the results of a pooled study analysis failed to identify any difference between the 
anterior-posterior and anterio-lateral pad placement in restoring sinus rhythm by the ECV. 
We performed protocol-based regular rhythm follow-up by Holter, the patients still have a 
high chance of subclinical paroxysmal AF between Holter evaluations.
In conclusions, the success rate of outpatient clinic-based ECV was 88.6% in this study, 
with a low complication rate, although 55.5% experienced recurrence of AF within 3 
months. Amiodarone was protective against short-term AF recurrences, and long-term AF 
recurrences were less in patients with baseline heart failure and potential recovery of their 
ventricular function.
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